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Strengths and limitations of this study
 ► The study might prove that surgeons can positively 
influence the satisfaction of their patients by a mi-
nor and inexpensive technical nuance (adding a burr 
hole cover before skin closure).
 ► By randomising patients with unilateral chronic sub-
dural haematoma (cSDH) into an intervention and 
control group, the effect of potential confounders 
should be minimised.
 ► The inclusion of patients with bilateral cSDH allows 
studying a completely unbiased effect of burr hole 
covers on the outcome of interest (as each patient 
serves as his/her own internal control).
 ► The 90- day period of the primary endpoint may be 
too short to detect a difference in outcome (as skin 
depressions progressively occur over time), but ad-
ditional 12- month outcome assessment should cap-
ture this.
AbStrACt
Introduction Outcomes rated on impairment scales are 
satisfactory after burr hole trepanation for chronic subdural 
haematoma (cSDH). However, the surgery leads to bony 
defects in the skull with skin depressions above that are 
frequently considered aesthetically unsatisfactory by the 
patients. Those defects could be covered by the approved 
medical devices (burr hole covers), but this is rarely done 
today. We wish to assess, whether the application of burr 
hole covers after trepanation for the evacuation of cSDH 
leads to higher patient satisfaction with the aesthetical 
result at 90 days postoperative, without worsening 
disability outcomes or increasing the complication rate.
Methods and analysis This is a prospective, single- 
blinded, randomised, controlled, investigator- initiated 
clinical trial enrolling 80 adult patients with first- time 
unilateral or bilateral cSDH in Switzerland. The primary 
outcome is the difference in satisfaction with the 
aesthetic result of the scar, comparing patients allocated 
to the intervention (burr hole cover) and control (no 
burr hole cover) group, measured on the Aesthetic 
Numeric Analogue scale at 90 days postoperative. 
Secondary outcomes include differences in the rates of 
skin depression, complications, as well as neurological, 
disability and health- related quality of life outcomes until 
12 months postoperative.
Ethics and dissemination The institutional review 
board (Kantonale Ethikkommission Zürich) approved this 
study on 29 January 2019 under case number BASEC 
2018–01180. This study determines, whether a relatively 
minor modification of a standard surgical procedure 
can improve patient satisfaction, without worsening 
functional outcomes or increasing the complication rate. 
The outcome corresponds to the value- based medicine 
approach of modern patient- centred medicine. Results 
will be published in peer- reviewed journals and electronic 
patient data will be safely stored for 15 years.
trial registration number NCT03755349.
IntroduCtIon
Outcome in terms of recovery of impaired 
neurological function is generally satisfactory 
after burr hole trepanation for the evacuation 
of chronic subdural haematoma (cSDH).1 2 
Despite being considered a relative minimally 
invasive type of surgery, it requires drilling 
holes in the patient’s skull. With progres-
sive haematoma reabsorption during the 
follow- up, patients may develop skin depres-
sions above the burr hole sites (figure 1).3 4 
Theoretically, burr holes could be covered by 
approved medical devices (burr hole covers) 
after cSDH evacuation and prior to closing 
the wound.
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Figure 1 Example of skin depression above the burr holes 
in a male patient in his late 80s, about 2 years following 
frontal and parietal burr hole trepanation for the evacuation 
of a large chronic subdural haematoma. The photo was 
taken with his permission and at this time. He continued 
to lead an active life. On inquiry, he and his wife confirmed 
feeling troubled by the well- visible and stigmatising skin 
depressions.
This has not become standard of care, however, and 
we previously set out to explore the prevalence and rele-
vance of skin depressions, as well as today’s pattern of 
care by conducting a cross- sectional survey- based study 
among neurosurgeons globally. Analysing 576 responses 
from 78 different countries, 76% of neurosurgeons stated 
that their patients complained about skin depressions 
after burr hole trepanations more or less frequently.5 
In contrary, only 28% of neurosurgeons currently apply 
burr hole covers more or less frequently for this indica-
tion. Their reluctance was mostly explained by a lack of 
evidence for any proven benefit, less so for the fear of 
an increased complication rate, technical difficulties and 
financial reasons. Around three- quarters (78% of neuro-
surgeons) indicated that they would consider applying 
burr hole covers for this indication, in case a high- quality 
trial demonstrated its efficacy and safety.5
We retrospectively reviewed a series of n=28 cSDH 
patients (64 burr holes) treated at our department, of 
which n=11 patients had received a burr hole cover on 
14 burr holes at the surgeon’s discretion. Applying the 
Aesthetic Numeric Analogue (ANA) scale to rate the 
aesthetical result of the surgery,6 patients rated sites where 
the burr hole was covered more favourably than sites 
where the burr hole was left uncovered (ANA 9.3±0.74 vs 
7.9±1.0; p<0.001).4 In addition, the rates of skin depres-
sion were as low as 7% in the intervention group and as 
high as 92% in the control group (p<0.001). Evidently, 
the prior results were subject to selection bias, patients 
were not blinded for the intervention and the study was 
underpowered to estimate possible group differences 
in complications.4 These preliminary findings were a 
promising starting point for further and more in- depth 
research, because filling this knowledge gap is likely to 
affect future management of cSDH patients.
MEthodS And AnAlySIS
 Study goals and objectives
The COveRs to impRove aesthetiC ouTcomeafter Surgery 
for Chronic subdural haemAtoma by buRr hole trepana-
tion trial aims to demonstrate that the placement of burr 
hole covers on the burr hole sites improves patient satis-
faction with the aesthetic outcome of the surgical proce-
dure at 3 and 12 months postoperative. It also aims to 
demonstrate that clinical outcomes (disability, neurolog-
ical function and health- related quality of life (hrQoL)) 
remain similar and complication rates (eg, surgical 
site infections (SSIs), cSDH recurrences, etc) are not 
increased by applying burr hole covers.
The primary objective is to compare mean ANA scores 
(patient satisfaction with the aesthetic result of the 
surgery) between the intervention and control group at 
90 days postoperatively. Secondary/safety objectives are 
to compare mean ANA scores, rates of skin depression, 
impairment in activities of daily living (ADLs), disability 
(modified Rankin scale (mRS)), hrQoL (Euro- Qol five 
dimension (EQ)−5D), neurological status (National Insti-
tute of Health Stroke scale (NIHSS)), complications and 
residual haematoma volume between the intervention 
and control group at 3 and 12 months postoperative.
 Study design
Prospective, single- blinded, randomised, controlled, 
investigator- initiated clinical trial. The trial is conducted 
at the University Hospital Zurich, Switzerland. The study 
will be reported according to the Consolidated Standards 
of Reporting Trials guidelines.7
Eligibility criteria
Participants fulfilling all of the following inclusion criteria 
are eligible for the study:
 ► Patients with first- time cSDH (hypodense, isodense, 
hyperdense or mixed type in CT imaging), scheduled 
for unilateral or bilateral double burr hole trepana-
tion under general anaesthesia.
 ► Patient age ≥18 years.
 ► Patient non- comatose at time of inclusion (Glasgow 
Coma Scale (GCS)>8 points).
 ► Patient able to communicate (in terms of ability to 
hear, see, speak and understand).
The presence of any one of the following exclusion 
criteria will lead to exclusion of the participant:
 ► Patient with recurrent cSDH or previous surgery for 
cSDH.
 ► Patient with cSDH treated by craniotomy or by single 
burr hole trepanation.
 ► Patient with cSDH treated in local anaesthesia.
 ► Patient unlikely to attend the follow- up (due to 
reasons of residency, dismal prognosis, etc).
 ► Pregnancy.
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Figure 2 Illustration of the algorithm of the CORRECT- 
SCAR trial. cSDH, chronic subdural haematoma; CORRECT- 
SCAR, COveRs to impRove aesthetiC ouTcome after Surgery 
for Chronic subdural haemAtoma by buRr hole trepanation.
 ► Known allergy against or incompatibility with titanium.
 ► Known or suspected non- compliance.
 ► Inability to follow the study procedures, for example, 
due to psychological disorders, dementia of the 
participant.
Intervention and study groups
A study algorithm can be found in figure 2 and table 1 
outlines all visits and procedures.
1. Patients with unilateral cSDH
All patients randomised into the control group will be 
treated according to our standard protocol for cSDH 
evacuation (online supplementary digital content 1).
All patients randomised into the intervention group 
will be treated according to our standard protocol for 
cSDH evacuation with one exception: placement of a 
burr hole cover (UN3 BURR HOLE COVER, 20 mm, 
W/TAB, Item code 53–34520, Stryker, Kalamazoo, 
Michigan, USA) that is fixed with two screws (UNIII 
AXS SCREWS, SELF- DRILLING, 1.5×4 MM, Item code 
56–15934, Stryker) on both burr holes after evacuation 
of the haematoma and prior to skin closure.
2. Patients with bilateral cSDH
Patients with bilateral cSDH serve as their own inter-
nal control. They are randomised concerning the in-
tervention or control side, being either the side with 
larger or smaller haematoma, respectively.
All patients are blinded concerning the study group/
side allocation. For application of the burr hole cover, 
surgeons will be instructed to firmly press the burr hole 
cover on the burr hole before receiving the screws from 
the scrub nurse in order to prevent from screws acciden-
tally falling into the subdural space. For this purpose, a 
standard operating procedure (SOP) has been developed 
(online supplementary digital content 2). No dexameth-
asone is applied to surgical candidates who are enrolled 
into this trial.
Primary outcome and follow-up
For the primary outcome, patient satisfaction with the 
aesthetic results of the scar is determined using a patient- 
rated outcome measure, the ANA scale,6 ranging from 0 
(dissatisfied) to 10 (very satisfied), at 90 days postoper-
ative. The outcome is assessed by mailed questionnaire 
and collected by a study coordinator.
Secondary outcomes
 ► Patient satisfaction with the aesthetic result of the scar, 
determined by the ANA scale, at 12 months postop-
eratively (mailed questionnaire, collected by a study 
coordinator).
 ► Impairment in ADLs (eg, when hairdressing, 
combing, washing, etc), rated as ‘yes’ versus ‘no’, at 
90 days and 12 months postoperative (mailed ques-
tionnaire, collected by a study coordinator).
 ► Rate of skin depression, rated as ‘yes’ versus ‘no’, at 90 
days and 12 months postoperative (mailed question-
naire, collected by a study coordinator).
 ► Disability, determined by the mRS (ranging from 0 
(no disability) to 6 (dead)) at 90 days.
 ► HrQoL, determined by the EQ- 5D (allowing 
the calculation of both the EQ- 5D index that 
ranges from 0.074 (worst hrQoL) to 1.00 (best 
hrQoL) using European norms and the EQ- 5D 
Visual Analogue Scale (VAS) (ranging from 0 (worst 
hrQoL) to 100 mm (best hrQoL)), at 90 days and 12 
months postoperative (mailed questionnaire, collected 
by a study coordinator).
 ► Neurological outcome, determined by the NIHSS 
(ranging from 0 (no neurological deficit) to 42 
(severe neurological deficit)), at 90 days.
 ► Home time, as surrogate marker of disability,8 at 90 
days and 12 months.
 Further safety outcomes
 ► Intraoperative and postoperative complications up 
to 90 days and 12 months, in particular cSDH recur-
rence and SSIs.
 ► Residual cSDH volume in ccm,3 absolute (ccm3) and 
relative (per cent) cSDH clearance at 90 days post-
operative (measured by two neuroradiologists inde-
pendently, otherwise not involved in the project, 
using volumetric analysis).
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Table 1 Tabular listing of schedule of events and assessments and procedures of the study
Study periods Before surgery Surgery Discharge from hospital 90- day follow- up 12- month follow- up
Visit 1 2 3 4 5
Time (days) 0 (-7–0) 0 5 (3–14) 90 (±10) 365 (±30)
Patient information and informed 
consent
x   (x) (x)   
Demographics x         
Medical history x         
Inclusion /exclusion criteria x         
Physical examination x   x x   
Laboratory examinations
Quick/INR/PTT
Thrombocyte count
  x
x
      
Randomisation x         
Other examinations (CT scan)
Haematoma volume
x
x
  x
x
x
x
  
Administer medical device (burr hole covers and 
screws)
x       
Primary outcome
Patient satisfaction (ANA) x x
Secondary outcomes
Impairment in ADLs x x
Skin depression x x
HrQoL (EQ- 5D) x x x
Disability (mRS) x x x
Neurological status (NIHSS) x x x
Complications (CDG) x x x
Adverse events x x x x B x
ADLs, activities of daily living; ANA, Aesthetic Numeric Analogue; CDG, Clavien- Dindo Grading; EQ- 5D, euroQol five dimension; HrQol, 
health- related quality of life; INR, international normalised ratio; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke 
Scale; PTT, partial thromboplastin time.
 Patient and public involvement
Other than recruiting patients admitted to our hospital, 
it is not intended to involve patients and the public in the 
design, conduct and reporting of this research.
EthICS And dISSEMInAtIon
Despite the generally favourable risk profile and outcome 
of burr hole trepanation for cSDH, skin depressions may 
occur weeks and months after haematoma reabsorption.3 4 
These are frequently considered aesthetically unsatisfac-
tory by patients and may lead to functional restrictions, 
for example, when combing, hairdressing or washing. In 
own clinical experience, patients reported being stared- at 
for these skin depressions, evoking feelings of aston-
ishment and aversion from both family members and 
strangers. With an increasing number of senior citizens 
in good physical/mental health and leading active social 
lives, the aesthetic aspect of outcome gains new impor-
tance. Today’s elderly patients do no longer content them-
selves with a basic surgical procedure, but—as informed 
customers—expect optimal surgical results topped with 
an excellent service.9
In theory, burr hole covers represent an effective, easy- 
to- apply and relatively inexpensive solution to prevent 
cosmetically and functionally unfavourable skin depres-
sions.4 Our survey has clearly demonstrated that—
in order to improve the acceptance of this technical 
nuance—its efficiency needs to be demonstrated first.5 
Moreover, as the intervention is unlikely to improve any 
‘hard outcome’ such as disability or survival, more data 
should substantiate its safety.
We consider a prospective, randomised, blinded and 
controlled study design optimal to prove a causal rela-
tionship between the study intervention and outcome. A 
clear strength of this study is that patients with bilateral 
cSDH can be included and serve as their own internal 
controls. Any retrospective approach to the study ques-
tion, or applying the burr hole cover in a prospective 
fashion and comparing it to a (historical) control group 
is not possible, as the outcome of interest (ANA scale) has 
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not been established in patients before, as well as for the 
likelihood of selection bias. The study aim corresponds 
to the value- based medicine approach of modern patient- 
centred medicine and results shall be published in peer- 
reviewed journals.
trial status
The study has started enrolling patients on 29 January 
2019.
 Safety considerations
Burr hole covers are applied according to an SOP (online 
supplementary digital content 2) and the medical device 
is approved for the studied application. All device defi-
ciencies, (severe) adverse event and (severe) adverse 
device effects are systematically recorded. The Clinical 
Trials Centre (CTC) of the University of Zurich externally 
monitors the trial.
Follow-up
Participating patients are followed up to 12 months 
postoperative.
 unblinding
Maintenance of trial treatment randomisation codes will 
be done by the electronic data capturing system (run by 
the CTC Zurich), using a built- in tool for randomisation. 
Breaking codes is not allowed. Unblinding (and revealing 
a participant’s allocated intervention) towards the patient 
is permissible only if the trial is suspended, prematurely 
terminated due to security concerns or completed.
 data managements and statistical analysis
The data are hosted by the CTC, University of Zurich. 
Electronic case report forms (eCRFs) are implemented. 
All data are stored on a server in a dedicated database. 
A role concept with personal passwords (site investigator, 
statistician, monitor, administrator, etc) regulates permis-
sion. Electronic patient data will be stored for 15 years 
until trial completion.
handling of missing data
First, the risk of missing data will be minimised by 
regular data reviews, also with an intention to identify 
at risk patients for lack of follow- up data. Even though 
the effect of skin depression is likely more pronounced 
at 12 months, compared with 90 days postoperative, we 
intentionally chose to select the 90- day time point as 
primary outcome in order to minimise drop- out. Contin-
gency plans foresee home/rehabilitation visits by study 
personnel to obtain otherwise missing data in patients 
who cannot show up for the planned 90 days or 12 months 
follow- up.10 Patients who die during the study interval 
(or cannot be evaluated as aphasic or in too poor clin-
ical condition) and in whom for this reason the primary 
endpoint cannot be obtained will be recorded as not 
assessable for the primary outcome. Sensitivity analyses 
will be performed for this study.
If, despite the above- mentioned mechanisms, missing 
data are present, we use the following protocol: first, 
mechanisms of missing data are assessed. If the data are 
deemed missing at random, and there is <10%–15% of 
patients with time point missing data, then case deletion 
will be used (and additional patients will be recruited). 
Second, if the missing data mechanism is not at random, 
multiple imputation will be performed, a well- accepted 
method for intention- to- treat (ITT) analysis in randomised 
controlled trial with missing outcome data.10 11
determination of sample size
Based on an expected mean satisfaction score of 9/10 on 
the ANA in the intervention and 7/10 on the ANA in the 
control group, n=37 patients need to be randomised in 
each study arm in order to find a statistically significant 
difference in the primary outcome with alpha set at 0.05, 
a power of 80% and an estimated SD of 3.4 Based on a 
total sample size of 2×37=74, with an estimated drop- out 
rate of 10%, we plan to include n=80 patients in total.
Methods used to minimise bias
A computerised randomisation tool, provided by the elec-
tronic data capturing system, is used with the only strata 
being unilateral or bilateral cSDH. The random alloca-
tion sequence is generated by the CTC, University of 
Zurich. Study physicians conduct patient enrolment and 
randomisation after basic patient data have been entered 
into eCRFs. Due to the randomisation process, patients 
with unilateral cSDH are likely to be well balanced for 
most important parameters that could potentially influ-
ence the primary outcome. In patients with bilateral 
cSDH, each patient serves as his/her own control, which 
minimises the risk of bias (=setting similar to that of a 
n- of-1 clinical trial but without repetitive crossover).12 13
Patients with unilateral cSDH will be randomised in a 
1:1 fashion into the intervention or control group, respec-
tively. Patients with bilateral cSDH will be randomised in a 
1:1 fashion concerning the intervention side, being either 
the side with more or lesser haematoma size (figure 2).
Patients will be blinded for allocation to the study 
group/side, but surgeons will not be. Patients will not 
be aware of the study group/side, since the operation 
takes place under general anaesthesia. The fact that 
patients are blinded for the study group allocation will be 
mentioned in the discharge letter (in order to inform the 
family physician), and the neurosurgical team of nurses 
and physicians will also be informed not to ‘unblind’ the 
patient.
The primary endpoint and most of the secondary 
endpoints will be determined by mailed questionnaires. 
This way, the patient will not be influenced by the pres-
ence of the physician when judging on satisfaction with 
the aesthetical result of the surgery. In addition, all data 
are collected by a dedicated study coordinator (EJ), who is 
not involved in the patient care (=independent outcome 
assessment).
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Primary analysis
The main analysis will be according to the ITT protocol. 
An as- treated analysis will be performed, additionally.
Satisfaction on the ANA scale for both the frontal and 
parietal scar are measured separately, but a mean satis-
faction score is built by adding the values and dividing 
the sum by two. For analysis of the primary outcome, the 
results obtained in the intervention group (unilateral 
cSDH) and on the intervention side (bilateral cSDH) will 
be combined and compared with the combined results 
obtained in the control group and on the control side. 
As the dependent variable is a quantitative variable on an 
interval scale, a rank- sum test is appropriate to analyse 
group differences. Even though no formal minimum 
clinically important difference (MCID) of the ANA scale 
has been determined, we powered the study to detect an 
in- between group difference in outcome of two points, 
as—abstracted from the numeric rating scale for pain 
(also ranging between 0 and 10)—a change of two points 
is considered to be well above the MCID,14 therefore, 
resulting in a clinically meaningful improvement for the 
patient.
Subgroup analyses will be made for patients with bald 
heads versus patients with scalp hair, male versus female 
patients, patients<60 years versus ≥60 years and for 
patients with bilateral cSDH.
Secondary analyses
As the remaining secondary outcomes are not side- 
specific but reflect the condition of the patient as a whole, 
the remaining secondary analyses will compare results 
obtained in patients with unilateral cSDH randomised 
into either the intervention or control group.
As the safety outcomes are specific for the incision site 
and side, for the safety analyses the results obtained in 
the intervention group and on the intervention side will 
be combined and compared with the combined results 
obtained in the control group and on the control side.
For the outcomes that are quantitative (hrQoL on the 
EQ- 5D) Student’s t- tests or rank- sum tests will be applied, 
depending on normally distributed data or not. For the 
outcomes that are categorical (type of impairment with 
ADLs, disability on the mRS, neurological outcome on 
the NIHSS, complications on the CDG) descriptive anal-
yses and X2 tests will be applied. For the outcomes that 
are binary (impairment with ADLs, skin depression, etc), 
logistic regression analysis will be performed, calculating 
the OR and 95% CIs.
Interim analyses
Once data of 50 patients with completed 90- day follow- up 
data have been collected, the primary endpoint and the 
safety analyses will be performed.
 Quality assurance
The study is conducted in accordance with Good Clin-
ical Practice guidelines. All source data are accessible 
for monitoring, audits and inspections. Authorities have 
the right to perform inspections and on- site auditing. 
External monitoring will be performed by the CTC, 
University of Zurich, as detailed in a monitoring plan 
including prestudy, site initiation, routine monitoring 
and close- out visits, considering local infrastructure, 
completeness of documents, patient safety, adherence to 
the study protocol, data quality entered into the eCRFs 
and the trial master file.
Progress of patient inclusion and data completeness is 
continuously (at least once every 2 weeks) checked by a 
study coordinator (EJ).
Expected outcomes of the study
The study will shed more light on the question, whether 
patient satisfaction with the aesthetic result of the surgical 
procedure can be improved by adding burr hole covers on 
the burr holes after trepanation for cSDH. An improve-
ment in patient satisfaction would likely be conferred 
through the decreased prevalence of skin depressions, 
as a strong difference in prevalence of skin depressions 
was previously found in two retrospective studies.3 4 The 
study will moreover allow to understand better, whether 
the application of burr hole covers increases the risks of 
complications, for example, cSDH recurrence or SSIs. 
Results of the study are likely to affect future manage-
ment of cSDH patients.5
duration of the project
Recruitment is expected to be completed by the end of 
January 2021, with final follow- up collected until January 
2022. Publication of the final results is expected around 
6 months after last patient out.
Project management
The principal investigators (MNS and MRG) are respon-
sible for patient inclusion, quality of data collection and 
adhesion to the protocol. They are supported by a team 
of site investigators, a dedicated study coordinator (EJ), 
the monitoring staff and the sponsor (LR).
All patients and/or next- of- kin will give written informed 
consent to contributing study physicians. Authorship for 
publications will be determined according to the recom-
mendation given by the International Committee of 
Medical Journal Editors. No use of professional writers 
is planned.
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